-- Data to be Presented at
In this randomized, double-blind, placebo-controlled Phase 2 trial, 236 patients with advanced pancreatic cancer received intravenous gemcitabine plus either intravenous simtuzumab (200 mg, n=76; 700 mg, n=79) or placebo (n=81) in cycles of 28 days. Median PFS for the simtuzumab 200 mg, simtuzumab 700 mg and placebo groups was 3.5 months, 3.7 months and 3.7 months, respectively. The difference in PFS between the simtuzumab and placebo arms was not statistically significant. Expected gemcitabine-related toxicities included anemia, thrombocytopenia, neutropenia and nausea. There was no difference in adverse events between patients taking simtuzumab versus placebo.
"Although simtuzumab did not provide clinical benefit in difficult-to-treat advanced pancreatic cancer patients in this study, we continue to explore simtuzumab in other areas of unmet medical need, with ongoing clinical trials in colorectal cancer, myelofibrosis and serious fibrotic lung and liver diseases," said
Simtuzumab is an investigational monoclonal antibody that is highly selective for LOXL2, an enzyme that modifies the extracellular matrix by promoting the cross-linking of collagen fibers. LOXL2 is thought to play an important role in tumor progression and metastasis and in the development of fibrotic diseases. Simtuzumab is being evaluated in several ongoing Phase 2 trials, including in combination with FOLFIRI for advanced colorectal cancer, in combination with ruxolitinib for myelofibrosis, as monotherapy for idiopathic pulmonary fibrosis, a rare lung disease, and for liver fibrosis caused by non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
Other agents in Gilead's oncology pipeline, including momelotinib and GS-5745, are currently being evaluated in clinical trials for the treatment of pancreatic cancer.
Additional information about clinical studies of simtuzumab and Gilead's other investigational cancer agents can be found at www.clinicaltrials.gov. Simtuzumab, momelotinib and GS-5745 are investigational products and their safety and efficacy have not been established.
About Gilead Sciences
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from clinical trials involving simtuzumab in other therapeutic areas. Gilead may also experience challenges in enrolling patients in clinical studies, requiring those studies to be modified or delayed. Further, Gilead may make a strategic decision to discontinue development of simtuzumab if, for example, Gilead believes commercialization will be difficult relative to other opportunities in its pipeline. As a result, simtuzumab may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended
For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936
Nathan Kaiser, 650-522-1853